Written by MarketBeatUpdated August 15, 2025 ShareLink copied to clipboard. Key Points MarketBeat identifies seven nanotechnology stocks to watch, which include Onto Innovation, OSI Systems, and Biodexa Pharmaceuticals, based on their recent trading volumes and growth potential. Onto Innovation has a market capitalization of $5.14 billion and a P/E ratio of 26.01, while OSI Systems shows a market cap of $3.80 billion and a P/E ratio of 27.53. Biodexa Pharmaceuticals is focused on developing treatments for Type 1 diabetes and rare brain cancers, with its lead product currently undergoing Phase II studies. Five stocks we like better than Onto Innovation. Like this article? Share it with a colleague. Link copied to clipboard. Featured Articles and OffersNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Elon’s Secret Social Security BombshellFrom Banyan Hill Publishing (Ad)NVIDIA Stock Could Pull Back in September, But Don’t Bet on ItBy Thomas Hughes | August 28, 2025Snowflake’s Snowballing Business and Robust Stock Price OutlookBy Thomas Hughes | August 28, 2025Tesla (NASDAQ:TSLA) Director Sells $42,034,800.00 in StockBy MarketBeat | September 1, 2025This Massive Market is Ripe for Disruption by this NasdaqFrom i2i Marketing Group, LLC (Ad)New Age Warfare: Anduril Is the Hype, AeroVironment Is the BuyBy Jeffrey Neal Johnson | August 28, 2025Chevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 2025 Recent Videos Stock ListsAll Stock Lists5G Biotech Blue Chip FAANG Gold Large Cap Marijuana Micro Cap Oil REITs Russell 2000 Small Cap Warren Buffett Investing ToolsCalendars and ToolsAnalyst RatingsCryptocurrency ScreenerCongressional TradingDividend IncreasesDividend CalculatorDividend CalendarEarnings AnnouncementsInsider TradesOptions Profit CalculatorPenny StocksPortfolio MonitoringShort InterestStock ComparisonsStock Market HolidaysStock Screener Search Headlines Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Written by MarketBeatUpdated August 15, 2025 ShareLink copied to clipboard. Key Points MarketBeat identifies seven nanotechnology stocks to watch, which include Onto Innovation, OSI Systems, and Biodexa Pharmaceuticals, based on their recent trading volumes and growth potential. Onto Innovation has a market capitalization of $5.14 billion and a P/E ratio of 26.01, while OSI Systems shows a market cap of $3.80 billion and a P/E ratio of 27.53. Biodexa Pharmaceuticals is focused on developing treatments for Type 1 diabetes and rare brain cancers, with its lead product currently undergoing Phase II studies. Five stocks we like better than Onto Innovation. Like this article? Share it with a colleague. Link copied to clipboard.
